Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
88 Results for "
Ternary Complex Formation
" in MedChemExpress (MCE) Product Catalog:
Products (88)
88 Results for "Ternary Complex Formation" in MCE Product Catalog:
Cat. No.: HY-180547
CAS No.: 3070832-68-4
Target:
Research Areas:
MRC71 is a TRIMTAC degrader that recruits endogenous TRIM21 E3 ligase at one end and covalently binds to HaloTag-fusion target proteins at the other end. MRC71 selectively degrades oligomeric CAV1- and Cavin1-mEGFP-Halo, but not monomeric mEGFP-Halo, and exhibits a typical concentration-dependent degradation profile with a hook effect. MRC71 can be used to verify TRIMTAC ternary complex formation and state-selective degradation in cells .
Cat. No.: HY-183718
Research Areas:
M4K3250 is a selective ALK2 PROTAC degrader with a pDC50 of 7.9. M4K3250 induces the formation of a ternary complex between ALK2 and the E3 ubiquitin ligase CRBN, thereby causing ALK2 degradation and inhibiting ALK2 activity. M4K3250 exhibits cytotoxicity in glioblastoma cells. M4K3250 can be used in studies related to glioblastoma .
Cat. No.: HY-183833
CAS No.: 2841473-77-4
Autophagy-IN-9 is a ATG5 inhibitor with an IC50 of 21.29 μM against ATG5-TECAIR. Autophagy-IN-9 blocks the binding of ATG5 to the hot-spot amino acid residues of TECAIR protein, disrupts the assembly of ATG5-related ternary complexes, inhibits autophagosome formation, and thereby downregulates cellular autophagy levels. Autophagy-IN-9 can be used in autophagy-related research, such as studies on infection .
Cat. No.: HY-206870
CAS No.: 3104965-33-2
Target:
Research Areas:
BP79 is a potent TSLP receptor inhibitor. BP79 disrupts TSLP-mediated ternary complex formation, blocks TSLPR-IL7Rα co-localization, binds and stabilizes TSLPR, and inhibits phosphorylated STAT3/6. BP79 suppresses immune cell infiltration, secretion of IL-13, IL-4. BP79 can be used for the research of inflammation diseases, such as atopic dermatitis, allergic asthma, and allergic rhinitis .
Cat. No.: HY-181756
CAS No.: 3061406-69-4
Target:
Research Areas:
LGF308 is a PROTAC degrader of BRD4 that exhibits selective cytotoxicity toward cancer cells over normal cells. LGF308 mediates the formation of a ternary complex between BRD4 and DCAF11 to achieve BRD4 degradation. LGF308 induces tumor cell apoptosis by upregulating apoptosis-related proteins. LGF308 inhibits tumor cell proliferation and migration in breast cancer and triple-negative breast cancer cell lines. LGF308 can be used for the research of breast cancer .
Cat. No.: HY-184913
JHK-02-102-1 is a selective CDK5 degrader derived from the regorafenib kinase inhibitor scaffold. JHK-02-102-1 recruits CRL4CRBN E3 ubiquitin ligase to induce ternary complex formation between CDK5 and CRBN, triggering ubiquitin-proteasome system-dependent degradation. JHK-02-102-1 achieves selectivity redirection from CDK6 to CDK5 via subtle PROTAC architecture modifications .
Cat. No.: HY-183115
CAS No.: 3127009-52-0
Target:
Research Areas:
TNG961 is a selective and orally active CRBN-mediated HBS1L molecular glue degrader. TNG961 induces formation of an HBS1L-TNG961-CRBN ternary complex, leading to potent degradation of HBS1L and secondary destabilization of its binding partner PELO. TNG961 can reduce HBS1L protein levels, thereby disrupting the PELO region involved in ribosome rescue. TNG961 can be used for the study of FOCAD-deficient cancers, such as pancreatic cancer .
Cat. No.: HY-14769B
CAS No.: 133978-76-4
Synonyms: 5,10-Methylenetetrafolate sodium; ANX-510 sodium
Target:
Research Areas:
Folitixorin sodium (5,10-Methylenetetrafolate sodium; ANX-510 sodium) is a reduced form of Folic acid (HY-16637) and a cofactor of thymidylate synthase . Folitixorin sodium acts as an essential cofactor to promote the formation of a tight ternary complex between thymidylate synthase and FdUMP, thereby enhancing the inhibitory effect of FdUMP on thymidylate synthase. Folitixorin sodium in combination with 5-fluorouracil and αVEGF reduces tumor volume in colorectal tumor models of nude mice. Folitixorin sodium is used in related research on Yoshida sarcoma, P-388 leukemia, and colorectal cancer .
Cat. No.: HY-183077
Research Areas:
BRD4 degrader-7 (Compound ZZ1) is a CTLH-dependent BRD4 degrader and c-Glue with a DC50 of 489 nM. BRD4 degrader-7 converts to a sulfinic acid derivative inside cells, interacts with the basic pocket of YPEL5, mediates the bridging of BRD4 BD1 to the YPEL5 subunit of the CTLH E3 ubiquitin ligase, and thereby promotes the formation of a ternary complex. BRD4 degrader-7 can be used in research on Ewing's sarcoma and leukemia .
Cat. No.: HY-183007
Target:
Research Areas:
LJM133 is a SMARCA2/PBRM1/SMARCA4 PROTAC degrader with DC50 values of 3.5 nM, 7 nM, and 6.4 nM. LJM133 induces ternary complex formation with VHL E3 ligase to drive proteasome-mediated degradation of target proteins. LJM133 suppresses cell proliferation and exhibits significant antitumor efficacy in a SMARCA4 mutant cancer xenograft model. LJM133 can be used for the research of cancer, such as SMARCA4 mutant non-small cell lung cancer .
Cat. No.: HY-184896
CAS No.: 3032314-99-8
Target:
Molecular Glues Eukaryotic Release Factor (eRF) c-Myc Androgen Receptor Kallikrein Ser/Thr Protease E1/E2/E3 Enzyme
Research Areas:
XYD113 is an orally active, selective GSPT1 Molecular glue degrader. XYD113 promotes the formation of the CRBN-GSPT1 ternary complex and mediates GSPT1 degradation in a CRBN-dependent manner via the ubiquitin-proteasome system. XYD113 downregulates genes associated with the occurrence and progression of prostate cancer (c-Myc, AR, AR-V7, KLK3, KLK2, TMPRSS2). XYD113 exhibits anticancer activity against prostate cancer. XYD113 can be used in the research of prostate cancer .
Cat. No.: HY-187225
Target:
Research Areas:
NCP07 is a PROTAC degrader targeting the coactivator-binding site (CBS) of ERα. NCP07 induces the formation of the ERα-NCP07-VHL ternary complex and promotes ERα degradation via the ubiquitin-proteasome system. NCP07 induces apoptosis and cell cycle arrest in endocrine therapy-resistant breast cancer cells. NCP07 inhibits the proliferation of wild-type and ESR1-mutant breast cancer cells. NCP07 is applicable to breast cancer-related research .
Cat. No.: HY-157830
CAS No.: 870120-63-1
Research Areas:
MDM2 ligand 6 is an MDM2 ligand that can be used in PROTAC synthesis-related research. MDM2 ligand 6 can serve as the target protein ligand moiety of the MDM2/GSPT1 PROTAC degrader WB156 (HY-174266) .
Cat. No.: HY-183115A
CAS No.: 3127008-95-8
Target:
Research Areas:
(Rac)-TNG961 is the rac isomer of TNG961 (HY-183115). TNG961 is a selective and orally active CRBN-mediated HBS1L molecular glue degrader. TNG961 induces formation of an HBS1L-TNG961-CRBN ternary complex, leading to potent degradation of HBS1L and secondary destabilization of its binding partner PELO. TNG961 can reduce HBS1L protein levels, thereby disrupting the PELO region involved in ribosome rescue. TNG961 can be used for the study of FOCAD-deficient cancers, such as pancreatic cancer .
Cat. No.: HY-184865
CAS No.: 3032493-76-5
Target:
Research Areas:
Anticancer agent 340 is an orally active antitumor agent. Anticancer agent 340 can bind to both the androgen receptor (AR) and BRD4 protein simultaneously, dose-dependently inducing the formation of the AR-BRD4 ternary complex, inhibiting the expression of the downstream target gene HEXIM1 (Gene X), and activating the Caspase 3/7 pathway to initiate apoptosis. Its proliferation inhibition and apoptosis activities are both significantly AR expression-dependent. Anticancer agent 340 can be used to study AR/BRD4 driven malignancies such as castration-resistant prostate cancer (CRPC) .
Cat. No.: HY-189201
Research Areas:
PinA1 is a selective Molecular glue degrader of CK1α with an EC50 of 2.09 µM. PinA1 induces the formation of a stable CRBN-PinA1-CK1α ternary complex to promote the polyubiquitination and subsequent proteasomal degradation of CK1α. PinA1 activates the p53 signaling pathway. PinA1 induces G1 cell cycle arrest. PinA1 induces p53-dependent Apoptosis. PinA1 can be used in studies related to acute myeloid leukemia .
Cat. No.: HY-W854844
CAS No.: 2913587-30-9
Research Areas:
JP-2-196 is a molecular glue that covalently targets the RING family E3 ligase RNF126. JP-2-196 also binds to RNF40, MID2, RNF219, RNF14, and LRSAM1. JP-2-196 induces the formation of ternary complexes between RNF126 and target proteins (e.g., BRD4, AR-V7), thereby promoting their ubiquitination and proteasomal degradation. JP-2-196 has potential for cancer research (such as prostate cancer and leukemia) .
Cat. No.: HY-180654
CAS No.: 3110272-60-8
Target:
Research Areas:
JWZ-8-103 is an orally active analog of PRLX-93936 (HY-119264) and a molecular glue targeting TRIM21. JWZ-8-103 increases the thermal stability of TRIM21. JWZ-8-103 promotes rapid and efficient interaction between TRIM21 and NUP98 (the apparent EC50 for ternary complex formation with the PRYSPRY domain of TRIM21 and the APD domain of NUP98 is approximately 20 μM), induces extensive ubiquitination and proteasomal degradation of numerous adjacent nucleoporins (NUPs, and thereby triggers cellular apoptosis. JWZ-8-103 can be used for the research of pancreatic cancer .
Cat. No.: HY-180654A
Target:
Research Areas:
JWZ-8-103 hydrochloride is an orally active analog of PRLX-93936 (HY-119264) and a molecular glue targeting TRIM21. JWZ-8-103 hydrochloride increases the thermal stability of TRIM21. JWZ-8-103 hydrochloride promotes rapid and efficient interaction between TRIM21 and NUP98 (the apparent EC50 for ternary complex formation with the PRYSPRY domain of TRIM21 and the APD domain of NUP98 is approximately 20 μM), induces extensive ubiquitination and proteasomal degradation of numerous adjacent nucleoporins (NUPs, and thereby triggers cellular apoptosis. JWZ-8-103 hydrochloride can be used for the research of pancreatic cancer .
Cat. No.: HY-181883
KRAS-IN-55 is a pan-KRAS inhibitor with IC50 values of 4.3, 9.6 and 1.6 nM against KRAS G12C, KRAS G12D and KRAS G12V, respectively. KRAS-IN-55 induces the formation of a new binding pocket on KRAS, thereby forming a high-affinity ternary complex with cyclophilin A (CYPA), inhibiting the interactions of KRAS with downstream effectors RAF and PI3K, and blocking oncogenic MAPK and PI3K signaling pathways. KRAS-IN-55 is applicable to cancer research such as colorectal cancer and non-small cell lung cancer .
